Ravidasvir

Ascletis Announces Cooperation with China Meheco International Co., Ltd. in Distribution of Its Ritonavir Tablets in Chinese Mainland

Retrieved on: 
Wednesday, April 13, 2022
Pegasys, COVID-19, PD-L1, HCV, Hepatitis B virus, HIV/AIDS, Patient, Distribution, Cornerstone, Danoprevir, Infection, THR, FASN, National Medical Products Administration, Gannex, Health, Hepatitis C, GBM, HKEX, Insurance, RNA, Occupational Safety and Health Act 1994, PBC, Hong Kong Stock Exchange, Medication, Shanghai Stock Exchange, CEO, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, NASH, R, OBI Pharma, Inc., Degenerative disease, United Kingdom, CHB, Acne, RNA polymerase II, Chinese Communist Party Committee Secretary, Ritonavir, AIDS, Ravidasvir, FXR, Generic drug, Vaccine, Pharmaceutical industry, Cancer

HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ --Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Ascletis Pharmaceuticals Co., Ltd. ("Ascletis Pharmaceuticals") has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavir tablets in Chinese mainland.

Key Points: 
  • HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ --Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Ascletis Pharmaceuticals Co., Ltd. ("Ascletis Pharmaceuticals") has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavir tablets in Chinese mainland.
  • Ascletis Pharmaceuticals is a wholly-owned subsidiary of Ascletis, and China Meheco International Co., Ltd. is a wholly-owned subsidiary of China Meheco Group Co., Ltd. ("China Meheco").
  • By this opportunity, we hope to explore various levels of cooperation with biotech companies in China such as Ascletis.
  • Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, said, "It's a great honor to cooperate with China Meheco in commercialization of ritonavir tablets.

Malaysia, First in the South East Asia to Offer Affordable and Efficacious Hepatitis C Treatment Solution

Retrieved on: 
Thursday, January 6, 2022
Viral hepatitis, World Health Organization, Patient, Sofosbuvir, Hepatitis, Ravidasvir, Disease, Expo, World, Hepatitis C, WHO, Industry, Infection, Death, Pharmaceutical industry, Health insurance

DUBAI, United Arab Emirates, Jan. 6, 2022 /PRNewswire/ -- Malaysia was featured as the Hepatitis C Treatment Hub of Asia at Expo 2020 Dubai during the opening ceremony of Malaysia Healthcare Excellence week at the Malaysia Pavilion. Being the first country in the world to be given conditional approval for Ravidasvir in combination with Sofosbuvir to treat Hepatitis C, Malaysia is poised to offer access to an affordable and efficacious treatment solution for those infected with the virus.

Key Points: 
  • Malaysia gains international attention as Hepatitis C Treatment Hub of Asia at Expo 2020 Dubai.
  • "In response to the World Hepatitis Day 2021 theme, "Hepatitis Can't Wait", Malaysia is ready and raring to move forward with a treatment solution for those infected with the disease.
  • This is in line with WHO's mission to reduce new viral hepatitis infections by 90% and reduce deaths by viral hepatitis by 65% by 2030.
  • Malaysia is offering Hepatitis C patients a treatment with a cure rate of 97% and cost reduction of 95%," said Chief Executive Officer of MHTC, Mohd Daud Mohd Arif,at the opening ceremony.

Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy

Retrieved on: 
Friday, December 3, 2021
Patient, National Science Board, Cornerstone, CEO, Pegasys, Safety, PD-L1, FASN, Drug, CDC classification system for HIV infection, HKEX, CHB, GBM, Hong Kong Stock Exchange, Occupational Safety and Health Act 1994, Program, Danoprevir, Disease, HCV, National Healthcare, Guideline, Gannex, Degenerative disease, National Healthcare Security Administration, FXR, Cirrhosis, Liver cancer, Hepatitis B virus, PBC, Treatment, Management process, Insurance, Phase, Acne, HIV/AIDS, Conditional sentence, Infection, R, NASH, Hepatitis C, Public health, Mortality, Ravidasvir, Hospital, NRDL, Viral hepatitis, THR, Pharmaceutical industry, Vaccine

HANGZHOU, China and SHAOXING, China, Dec. 2, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021) (《国家基本医疗保险、工伤保险和生育保险药品目录（2021）年》) (the "National Reimbursement Drug List" or the "NRDL"). 

Key Points: 
  • The results from the Phase II/III clinical trials in China with the all-oral direct anti-HCV ASCLEVIR / GANOVO regimen showed a 99% cure rate in genotype 1 non-cirrhosis HCV patients.
  • ASCLEVIR is a pan-genotypic NS5Ainhibitor with high genetic barrier to resistance, with a cure rate of 100% in patients with baseline NS5Aresistance.
  • "The assessment by National Healthcare Security Administration ("NHSA") is based on multi-factors including efficacy, safety, economy, novelty and fairness.
  • Ascletis will continue to support the country's healthcare system and contributes to the national 'Healthy China' strategy."